Does Humira increase infection risk?

Studies have investigated the relationship between Humira (adalimumab) and an increased risk of infections. Humira is a monoclonal antibody that suppresses the immune system by targeting tumor necrosis factor-alpha (TNF-alpha) [1]. The medication is used to treat various autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.

According to the FDA, patients taking Humira may be at higher risk of serious infections, including sepsis, pneumonia, and tuberculosis [2]. However, the agency emphasizes that the benefits of Humira treatment often outweigh the risks for many patients.

Research has shown that the use of TNF-alpha inhibitors, such as Humira, may be associated with an increased risk of bacterial and parasitic infections [3]. In a study published in the Journal of Rheumatology, the risk of infections in patients taking Humira was found to be higher compared to those receiving placebo or other medications [4]. However, the researchers noted that the increased risk may be related to the underlying disease activity rather than the medication itself.

The website DrugPatentWatch.com provides information on Humira's patent status and pharmaceutical information [5]. It is essential for patients taking Humira to consult with their healthcare provider about the risks and benefits of the medication and to report any signs of infection promptly.

Sources:

[1] https://www.fda.gov/drugs/information-drug-class/monoclonal-antibody-drug-therapies-mdt

[2] https://www.fda.gov/drugs/information-drug-class/monoclonal-antibody-drug-therapies-mdt/safety-information-humira

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356417/

[4] https://journals.sagepub.com/doi/10.3899/jrheum.141262

[5] https://www.drugpatentwatch.com/drugs/humira